From cluster 1, it can be inferred that the focus likely pertained to gene expression and biological properties of KRAS in various cancer cells encompassing breast cancer, cholangiocarcinoma, and pancreatic cancer. This evidence concerns the gene KRAS and cholangiocarcinoma.